+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
ID07798505

Safety and Pharmacokinetics Study of HMB-003 Drug in Healthy Adults Aged 18 to 50

Led by Hemab ApS · Updated on 2026-09-10

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a new drug called HMB-003 in healthy adult volunteers aged 18 to 50 years. The study aims to evaluate how well participants tolerate this drug and to monitor any important side effects. Additionally, the study will measure how much HMB-003 is present in the body after a single injection. Participants will receive a single subcutaneous dose of HMB-003 or a placebo, assigned randomly in different dose levels within separate groups. This is a phase 1, double-blind trial where neither participants nor researchers know who receives the drug or placebo. The dosing is done once, and participants belong to parallel groups based on their assigned dose cohort. During the study, participants will be monitored for up to 42 days after dosing. This includes tracking any treatment-related adverse events, measuring the concentration of HMB-003 in plasma and urine, and assessing pharmacodynamic effects like clot lysis over time. Researchers will perform physical exams, vital sign checks, laboratory tests, and ECGs to ensure participant safety throughout the study period.

CONDITIONS

Brief Title

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

Research Team

C

Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here